
The Cooper Companies company profile
$62.65+0.74%Close 13 Nov 2026 · Market value $11.91B · Next results 3 Dec 2026
About The Cooper Companies
The Cooper Companies, Inc. is a global medical device company headquartered in San Ramon, California, selling products in over 130 countries. It operates two business segments. CooperVision manufactures contact lenses, including single-use, two-week and monthly lenses in spherical, toric and multifocal designs, and myopia management products such as the MiSight 1 day lens. CooperSurgical offers products and services in fertility and women's health, including medical devices used in gynecology, obstetrics and labor and delivery, fertility laboratory products, cryostorage of cord blood and cord tissue, genomic services, and the Paragard intrauterine device. CooperVision sells to optical chains, global retailers, buying groups and mass merchandisers, while CooperSurgical sells to OB/GYN and medical offices, hospitals, ambulatory surgery centers, fertility clinics and directly to consumers.
A summary of the business section of the company's latest annual report, filed 5 Dec 2025.
Company facts
| Ticker | COO · Nasdaq |
|---|
| Sector | Medical devices |
|---|
| Industry | Health Care Supplies |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 October |
|---|
| Reporting currency | USD |
|---|
| CIK | 711404 |
|---|
| Latest annual report | 10-K, filed 5 Dec 2025 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Albert G. White III | President & CEO · Director | 1.9M · 1% | Shares withheld for tax, 8 Jan 2026 |
|---|
| Daniel G. McBride | EVP & Chief Operating Officer | 686K · < 1% | Option exercise, 8 Jan 2026 |
|---|
| Robert S. Weiss | Director | 547K · < 1% | Option exercise, 1 Apr 2026 |
|---|
| Holly R. Sheffield | President, CSI | 358K · < 1% | Option exercise, 8 Jan 2026 |
|---|
| Brian G. Andrews | EVP, CFO & Treasurer | 350K · < 1% | Option exercise, 8 Jan 2026 |
|---|
| Gerard H. Warner III | President, CooperVision, Inc. | 91.1K · < 1% | Shares withheld for tax, 8 Jan 2026 |
|---|
| Colleen E. Jay | Director | 36.6K · < 1% | Option exercise, 1 Apr 2026 |
|---|
| Teresa S. Madden | Director | 12.4K · < 1% | Option exercise, 1 Apr 2026 |
|---|
| Maria Rivas, M.D. | Director | 11.1K · < 1% | Option exercise, 1 Apr 2026 |
|---|
| Walter M Rosebrough, Jr. | Director | 10.0K · < 1% | Open-market purchase, 14 Sep 2026 |
|---|
| Cynthia L. Lucchese | Director | 9.4K · < 1% | Option exercise, 1 Apr 2026 |
|---|
| Lawrence E. Kurzius | Director | 7.8K · < 1% | Open-market purchase, 16 Sep 2026 |
|---|
| Barbara A. Carbone | Director | 0 · < 1% | Option exercise, 1 Apr 2026 |
|---|
| Keel Paul A | Director | — | Open-market purchase, 11 Sep 2026 |
|---|
| KOZY WILLIAM A | Director | — | Option exercise, 1 Apr 2025 |
|---|
| Ricupati Agostino | SVP & CAO | — | Option exercise, 1 Apr 2025 |
|---|
| Khadder Nicholas | VP, General Counsel & Corp Sec | — | Option exercise, 8 Jan 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
COO in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.